Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 747 results
Found 747 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

G

Ranade K, Geese WJ, Noor M, et al. "Genetic analysis implicates resistin in HIV lipodystrophy." AIDS. 2008;22(13):1561-8.
Pillai SK, Pond SLKosakovs, Liu Y, et al. "Genetic attributes of cerebrospinal fluid-derived HIV-1 env." Brain. 2006;129(Pt 7):1872-83.
Cespedes MS, Kerns SL, Holzman RS, McLaren PJ, Ostrer H, Aberg JA. "Genetic predictors of cervical dysplasia in African American HIV-infected women: ACTG DACS 268." HIV Clin Trials. 2013;14(6):292-302.
Figueroa DB, Madeen EP, Tillotson J, et al. "Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells." AIDS Res. Hum. Retroviruses. 2018;34(5):421-429.
Gianella S, Marconi VC, Berzins B, et al. "Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy." J. Acquir. Immune Defic. Syndr.. 2018;79(5):e112-e114.
Bartha I, Carlson JM, Brumme CJ, et al. "A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control." Elife. 2013;2:e01123.
Johnson DH, Venuto C, Ritchie MD, et al. "Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2014;24(4):195-203.
Henrich TJ, McLaren PJ, Rao SSP, et al. "Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study." Open Forum Infect Dis. 2014;1(1):ofu018.
Leger PD, Johnson DH, Robbins GK, et al. "Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384." J. Neurovirol.. 2014;20(3):304-8.
Holzinger ER, Grady B, Ritchie MD, et al. "Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants." Pharmacogenet. Genomics. 2012;22(12):858-67.
Wanga V, Venuto C, Morse GD, et al. "Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2015;25(9):450-61.
Lehmann DS, Ribaudo HJ, Daar ES, et al. "Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols." Pharmacogenet. Genomics. 2015;25(2):51-9.
Lorenzana SB, Hughes MD, Grinsztejn B, et al. "Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial." AIDS. 2012;26(9):1083-93.
Anderson JA, Jiang H, Ding X, et al. "Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection." AIDS Res. Hum. Retroviruses. 2008;24(5):685-94.
McMahon DK, Zheng L, Hitti J, et al. "Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV." Clin. Infect. Dis.. 2013;56(7):1044-51.

H

Abu-Raddad LJ, Barnabas RV, Janes H, et al. "Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?" AIDS. 2013;27(6):981-9.
Kemmer N, Hua L, Andersen JW, Chung RT, Butt AA, Sherman KE. "Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study." J. Viral Hepat.. 2012;19(11):792-800.
Behler CM, Vittinghoff E, Lin F, et al. "Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects." Clin. Infect. Dis.. 2007;44(10):1375-83.
Hulgan T, Tebas P, Canter JA, et al. "Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy." J. Infect. Dis.. 2008;197(6):858-66.
Kallianpur AR, Hulgan T, Canter JA, et al. "Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy." AIDS. 2006;20(11):1503-13.
Kallianpur AR, Gerschenson M, Hulgan T, et al. "Hemochromatosis (HFE) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy." AIDS Res. Hum. Retroviruses. 2018;34(11):942-949.
Cramer YS, Rosenkranz SL, Hall SD, Szczech LA, Amorosa V, Gupta SK. "Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177." J. Acquir. Immune Defic. Syndr.. 2010;54(4):e7-9.
Sherman KE, Rouster SD, Stanford S, et al. "Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens." J. Infect. Dis.. 2010;201(5):712-9.
Hua L, Andersen JW, Daar ES, Glesby MJ, Hollabaugh K, Tierney C. "Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment." AIDS. 2013;27(17):2725-34.
Haas DW, Koletar SL, Laughlin L, et al. "Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir." J. Acquir. Immune Defic. Syndr.. 2009;50(3):290-3.
Ngongondo MN, Miyahara S, Hughes MD, et al. "Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial." J. Acquir. Immune Defic. Syndr.. 2018;78(1):54-61.
Celum C, Hong T, Cent A, et al. "Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study." J. Infect. Dis.. 2017;215(6):907-910.
Cachay ER, Frost SDW, Richman DD, Smith DM, Little SJ. "Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection." J. Infect. Dis.. 2007;195(9):1270-7.
Healy B, Degruttola V. "Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses." Biostatistics. 2007;8(2):438-52.
Huang Y, Liu D, Wu H. "Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system." Biometrics. 2006;62(2):413-23.

Pages